RANCHO CORDOVA, Calif., June 12, 2013 (GLOBE NEWSWIRE) -- ThermoGenesis Corp. (Nasdaq:KOOL), a leading supplier of enabling technologies for the processing and storage of stem cells and other biological tissues, today said its AXP® AutoXpress® System (AXP) has been selected by the United Kingdom's NHS Blood and Transplant (NHSBT) and will be implemented through a new, five-year exclusive agreement. NHSBT manages six cord blood collection facilities and operates a cord blood bank laboratory in Filton, Bristol, U.K. The Company expects to begin recording initial revenues under the agreement within the next several weeks.
ThermoGenesis Announces New AXP(R) Customer In The United Kingdom
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.